A Phase 2 interventional study of LUM/IVA and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 2 sites in Netherlands. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-10-02.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 20th largest by enrollment, is one of 2 that started in 2017, is one of 4 in phase 2, and was the 16th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →
lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2017.
This study's enrollment of 20 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 66 across the 20 interventional studies. Of the 20 that completed or were terminated, 15 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 1 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 103rd largest by enrollment of the 116 interventional ones that give a count, is one of 7 that started in 2017, is one of 21 in phase 2, and was the 62nd registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, crossover study that will evaluate the efficacy of LUM/IVA in subjects with CF 12 years of age and older who have at least one A455E mutation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LUM/IVA in Treatment Period 1; washout; placebo in Treatment Period 2
Drug: LUM/IVA · Drug: Placebo
Placebo in Treatment Period 1; washout; LUM/IVA in Treatment Period 2
Drug: LUM/IVA · Drug: Placebo
Drug pages: Lumacaftor · Ivacaftor
LUM 400 mg/IVA 250 mg every 12 hours (q12h)
Also known as: lumacaftor/ivacaftor
No Active Drug
Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 8
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Study Baseline, Through Week 8
A total of 20 subjects were enrolled in this cross-over study.
| Milestone | Sequence 1: First LUM/IVA, Then Placebo | Sequence 2: First Placebo, Then LUM/IVA |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
| Milestone | Sequence 1: First LUM/IVA, Then Placebo | Sequence 2: First Placebo, Then LUM/IVA |
|---|---|---|
| Started | 10 | 10 |
| Completed | 8 | 9 |
| Not completed | 2 | 1 |
| Withdrew: Adverse event | 2 | 1 |
| Milestone | Sequence 1: First LUM/IVA, Then Placebo | Sequence 2: First Placebo, Then LUM/IVA |
|---|---|---|
| Started | 8 | 9 |
| Completed | 8 | 9 |
| Not completed | 0 | 0 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| Percentage of predicted FEV1 | Placebo | LUM/IVA |
|---|---|---|
| Absolute Change From Study Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) Through Week 8 | 2.6 (0.2 to 4.9) | 2.7 (0.3 to 5.0) |
Collected over Up to Week 28. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/18 (0%) | 0/18 (0%) | 13/18 (72.2%) |
| LUM/IVA | 0/19 (0%) | 0/19 (0%) | 15/19 (78.9%) |
| Event | Placebo | LUM/IVA |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/18 | 8/19 |
| HeadacheNervous system disorders | 0/18 | 4/19 |
| FlatulenceGastrointestinal disorders | 0/18 | 4/19 |
| NauseaGastrointestinal disorders | 0/18 | 4/19 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 3/18 | 3/19 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/18 | 2/19 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/18 | 2/19 |
| Abdominal painGastrointestinal disorders | 3/18 | 2/19 |
| FatigueGeneral disorders | 2/18 | 3/19 |
| NasopharyngitisInfections and infestations | 2/18 | 3/19 |
| Age, Continuous(years) | Sequence 1: First LUM/IVA, Then Placebo | Sequence 2: First Placebo, Then LUM/IVA | Total |
|---|---|---|---|
| Mean | 41.2 ± 15.1 | 34.7 ± 11.8 | 38.0 ± 13.6 |
| Sex: Female, Male(Participants) | Sequence 1: First LUM/IVA, Then Placebo | Sequence 2: First Placebo, Then LUM/IVA | Total |
|---|---|---|---|
| Female | 7 | 5 | 12 |
| Male | 3 | 5 | 8 |
| Ethnicity (NIH/OMB)(Participants) | Sequence 1: First LUM/IVA, Then Placebo | Sequence 2: First Placebo, Then LUM/IVA | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 10 | 10 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sequence 1: First LUM/IVA, Then Placebo | Sequence 2: First Placebo, Then LUM/IVA | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 10 | 10 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Sep 2017, 7 months.
Results were first posted in Oct 2018, 1 year after primary completion.
Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 7 months is below that.
Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lumacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →